RNA Technologies is a privately held RNA-focused company headquartered in Montreal, Quebec, Canada, led by CEO Claude Leduc. The website does not state a founding date or employee count. The company positions itself around two lines of business, RNA Technology Services and RNA Therapeutic Services, and states a goal of becoming a leader in optimised, engineered, high-quality mRNA for personalised medicine and targeted therapeutics.

In February 2024, the company announced a government loan, delivered through the Economic Development Agency of Canada for the Regions of Quebec, to purchase laboratory technology. In June 2024, it inaugurated new Montreal laboratories, apparently in connection with the IRCM (Institut de recherches cliniques de Montréal), which also hosted an RNA Medicine and Innovation Symposium that the company promoted. RNA T&T also took part in BIO 2024 and lists a partnerships and collaborations page referencing research institution and industry alliances.

Its services are aimed at preclinical research and early translational work. The site mentions no GMP certification, clinical-grade manufacturing, or named commercial clients.

Key Products and Services

RNA Technology Services

• Off-the-shelf reporter mRNA, including luciferase, eGFP, and mCherry
• Custom in vitro transcribed RNA (mRNA, lncRNA) from a few hundred nucleotides up to 5,000 nt, at scales from 1 mg to grams
• Rapid screening service producing hundreds of sequence variants for therapeutic applications
• Codon and sequence optimisation for improved expression
• UTR optimisation for improved translation efficiency
• Encapsulation in commercially available LNPs, with targeted LNPs also available

Quality Control

• RNA QC covering integrity (Bioanalyzer), transcription identity (sequencing), and dsRNA removal (dot immunoblots)
• LNP QC covering particle size (dynamic light scattering), surface charge, encapsulation efficiency and concentration (RiboGreen assay), pH, and osmolarity

RNA Therapeutic Services

• Supply of high-quality in vitro transcribed RNA and collaborative development with biotech companies and academic partners
• Applications in vaccine development, gene therapy, stem cell reprogramming, non-viral gene therapy, and custom protein expression for personalised medicine

RNA Technologies occupies the preclinical and early translational segment of the RNA supply chain. Its customers are research groups and biotechs that need optimised, quality-controlled mRNA and LNP material before committing to GMP manufacturing at larger CDMOs. Its offering centres on sequence and UTR engineering, rapid candidate screening, and documented QC, which suits teams working on delivery and expression challenges in mRNA therapeutics rather than vaccines at commercial scale. Its Montreal base gives it access to the Quebec RNA research ecosystem and Canadian government support. Its public presence is small, with limited disclosure of scale, certifications, and clients.